NASDAQ$IDYA
IDEAYA Biosciences Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
IDEAYA Biosciences reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.
IDEAYA Biosciences reported a net loss of $130.3 million for the three months ended December 31, 2024. As of December 31, 2024, IDEAYA had cash, cash equivalents and marketable securities of approximately $1.1 billion, anticipated to fund operations into at least 2028.
- Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025.
- 95 patients enrolled in neoadjuvant UM trial and targeting clinical data and regulatory update(s) in H1 2025, including vision data in plaque brachytherapy patients.
- Ph1 initiated for Werner Helicase IDE275 (GSK959) and received $7 million milestone from GSK, and targeting medical conference update in H1 2025.
- IDEAYA entered into an exclusive global license agreement for IDE849 outside of Greater China with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) in December 2024.
Headline financials
Revenue & EPS history
IDEAYA · Revenue · Quarterly
$7M
Revenue by segment
IDEAYA · $8.04M total across 1 segment · Q3 2023
- Collaboration Revenue$8.04M—100.0%
Forward guidance
IDEAYA is targeting multiple clinical data readouts and program updates across its clinical pipeline in 2025.
Tailwinds
- Targeting median progression free survival (PFS) readout for Phase 2/3 registration-enabling trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative MUM by year-end 2025.
- A clinical update in over 75 patients in the Company-sponsored Phase 2 trial and regulatory update(s) is targeted for the first half of 2025, including vision data in plaque brachytherapy patients.
- Targeting Phase 1/2 expansion in the first quarter of 2025 and clinical data update for IDE397 in combination with Trodelvy® in MTAP-deletion UC in 2025.
- IDEAYA plans to enable wholly-owned IDE397 combination with IDE892 in patients with MTAP-deletion non-small cell lung cancer (NSCLC) in the second half of 2025.
- Data highlighting IDE275's differentiated potential best-in-class profile will be presented with GSK at a medical conference in the first half of 2025.
Headwinds
- IDEAYA and Amgen mutually agreed to wind down the IDE397 and AMG 193 clinical combination study in February 2025, and will not pursue dose expansion.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.4%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+6.7%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+40.5%
Q3 2019
Best reaction
-31.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -1.9% | +1.2% | |
| Q4 2025 | +1.6% | +5.6% | +7.7% | |
| Q3 2025 | -2.7% | -3.6% | +14.8% | |
| Q1 2025 | +2.9% | +10.6% | +28.1% | |
| Q4 2024 | -5.4% | -6.9% | -15.4% | |
| Q3 2024 | +3.4% | +9.4% | -0.9% | |
| Q2 2024 | -3.1% | +2.4% | +1.0% | |
| Q1 2024 | -3.9% | -4.5% | -8.0% | |
| Q4 2023 | -6.0% | -2.7% | -3.2% | |
| Q3 2023 | +6.9% | +1.6% | +8.1% | |
| Q2 2023 | +1.2% | +3.3% | +12.9% | |
| Q1 2023 | +15.6% | +10.2% | +31.5% | |
| Q4 2022 | +2.1% | -8.7% | -16.0% | |
| Q3 2022 | -3.4% | -1.8% | -2.5% | |
| Q2 2022 | -31.4% | -34.8% | -20.1% | |
| Q1 2022 | +13.0% | +26.4% | +48.4% | |
| Q4 2021 | -2.2% | +3.8% | -11.1% | |
| Q3 2021 | +3.9% | +0.8% | -4.1% | |
| Q2 2021 | -3.5% | +1.0% | +14.1% | |
| Q1 2021 | +7.8% | +1.7% | +12.5% | |
| Q4 2020 | -8.2% | -2.8% | -15.9% | |
| Q3 2020 | +2.5% | +6.3% | +9.3% | |
| Q2 2020 | -1.2% | -1.7% | +4.8% | |
| Q1 2020 | -9.4% | -0.6% | -5.3% | |
| Q4 2019 | +13.6% | +14.9% | +40.8% | |
| Q3 2019 | +40.5% | +30.6% | +29.6% | |
| Q2 2019 | +6.0% | -1.5% | +19.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro